Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial

Solomon Jo, Agnes Juhasz, Keqiang Zhang, Christopher Ruel, Sofia Loera, Sharon P. Wilczynski, Yun Yen, Xiyong Liu, Joshua Ellenhorn, Dean Lim, Benjamin Paz, George Somlo, Nayana Vora, Stephen Shibata

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The aim of this study was to determine the presence of high-risk HPV-16 in patients with HNSCC, assess the impact of HPV status on treatment response and survival in this select cohort treated with combined modality therapy and to identify the differences in HIF-1α and VEGF expression in HPV-positive and -negative tumors. Patients and Methods: Patients had resectable, untreated stage III, IV HNSCC of the oral cavity, oropharynx, hyopharynx or larynx, and stage II cancer of the base of tongue, hypopharynx and larynx. HPV status was determined by conventional PCR in fresh frozen biopsy samples and by Taqman PCR assay on formalin-fixed, paraffin-embedded specimens. HIF-1α and VEGF expression were assessed by quantitative real-time PCR (RT-PCR). Multivariate Cox proportional hazards regression analysis was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) based on HPV status. Results: HPV-16 was detected in 14 of 24 evaluable cases. There were no significant differences in response rates after neoadjuvant chemotherapy (86% vs. 90%) in HPV-positive and HPV-negative patients, respectively. There was a trend toward better progression-free (HR=0.15, 95% CI=0.002-12.54; p=0.06) and overall survival (HR=0.14, 95% CI=0.001-14.12; p=0.10) for HPV-positive patients. In a subset of 13 fresh frozen samples, RT-PCR revealed a significant increase in VEGF mRNA levels in HPV-positive tumors (p<0.01).No difference was seen for HIF-1α expression. Conclusion: HPV presence portended a better prognosis in patients with oropharyngeal SCC treated with a multimodality treatment in a prospective clinical trial. The level of VEGF mRNA was up-regulated in HPV-16-positive tumors possibly through an HIF-1 independent manner.

Original languageEnglish
Pages (from-to)1467-1474
Number of pages8
JournalAnticancer Research
Volume29
Issue number5
Publication statusPublished - May 1 2009
Externally publishedYes

Fingerprint

Phase II Clinical Trials
Papillomavirus Infections
Squamous Cell Carcinoma
Vascular Endothelial Growth Factor A
Human papillomavirus 16
Confidence Intervals
Real-Time Polymerase Chain Reaction
Tongue Neoplasms
Hypopharynx
Combined Modality Therapy
Neoplasms
Polymerase Chain Reaction
Messenger RNA
Oropharynx
Laryngeal Neoplasms
Survival
Larynx
Paraffin
Formaldehyde
Mouth

Keywords

  • Human papillomavirus
  • Hypoxia-inducible factor-1α
  • Oropharyngeal squamous cell carcinoma
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Jo, S., Juhasz, A., Zhang, K., Ruel, C., Loera, S., Wilczynski, S. P., ... Shibata, S. (2009). Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. Anticancer Research, 29(5), 1467-1474.

Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. / Jo, Solomon; Juhasz, Agnes; Zhang, Keqiang; Ruel, Christopher; Loera, Sofia; Wilczynski, Sharon P.; Yen, Yun; Liu, Xiyong; Ellenhorn, Joshua; Lim, Dean; Paz, Benjamin; Somlo, George; Vora, Nayana; Shibata, Stephen.

In: Anticancer Research, Vol. 29, No. 5, 01.05.2009, p. 1467-1474.

Research output: Contribution to journalArticle

Jo, S, Juhasz, A, Zhang, K, Ruel, C, Loera, S, Wilczynski, SP, Yen, Y, Liu, X, Ellenhorn, J, Lim, D, Paz, B, Somlo, G, Vora, N & Shibata, S 2009, 'Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial', Anticancer Research, vol. 29, no. 5, pp. 1467-1474.
Jo, Solomon ; Juhasz, Agnes ; Zhang, Keqiang ; Ruel, Christopher ; Loera, Sofia ; Wilczynski, Sharon P. ; Yen, Yun ; Liu, Xiyong ; Ellenhorn, Joshua ; Lim, Dean ; Paz, Benjamin ; Somlo, George ; Vora, Nayana ; Shibata, Stephen. / Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. In: Anticancer Research. 2009 ; Vol. 29, No. 5. pp. 1467-1474.
@article{3af40e8e1db04168b39aa232d4c9643a,
title = "Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial",
abstract = "The aim of this study was to determine the presence of high-risk HPV-16 in patients with HNSCC, assess the impact of HPV status on treatment response and survival in this select cohort treated with combined modality therapy and to identify the differences in HIF-1α and VEGF expression in HPV-positive and -negative tumors. Patients and Methods: Patients had resectable, untreated stage III, IV HNSCC of the oral cavity, oropharynx, hyopharynx or larynx, and stage II cancer of the base of tongue, hypopharynx and larynx. HPV status was determined by conventional PCR in fresh frozen biopsy samples and by Taqman PCR assay on formalin-fixed, paraffin-embedded specimens. HIF-1α and VEGF expression were assessed by quantitative real-time PCR (RT-PCR). Multivariate Cox proportional hazards regression analysis was used to calculate hazard ratios (HRs) and 95{\%} confidence intervals (CIs) based on HPV status. Results: HPV-16 was detected in 14 of 24 evaluable cases. There were no significant differences in response rates after neoadjuvant chemotherapy (86{\%} vs. 90{\%}) in HPV-positive and HPV-negative patients, respectively. There was a trend toward better progression-free (HR=0.15, 95{\%} CI=0.002-12.54; p=0.06) and overall survival (HR=0.14, 95{\%} CI=0.001-14.12; p=0.10) for HPV-positive patients. In a subset of 13 fresh frozen samples, RT-PCR revealed a significant increase in VEGF mRNA levels in HPV-positive tumors (p<0.01).No difference was seen for HIF-1α expression. Conclusion: HPV presence portended a better prognosis in patients with oropharyngeal SCC treated with a multimodality treatment in a prospective clinical trial. The level of VEGF mRNA was up-regulated in HPV-16-positive tumors possibly through an HIF-1 independent manner.",
keywords = "Human papillomavirus, Hypoxia-inducible factor-1α, Oropharyngeal squamous cell carcinoma, Vascular endothelial growth factor",
author = "Solomon Jo and Agnes Juhasz and Keqiang Zhang and Christopher Ruel and Sofia Loera and Wilczynski, {Sharon P.} and Yun Yen and Xiyong Liu and Joshua Ellenhorn and Dean Lim and Benjamin Paz and George Somlo and Nayana Vora and Stephen Shibata",
year = "2009",
month = "5",
day = "1",
language = "English",
volume = "29",
pages = "1467--1474",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial

AU - Jo, Solomon

AU - Juhasz, Agnes

AU - Zhang, Keqiang

AU - Ruel, Christopher

AU - Loera, Sofia

AU - Wilczynski, Sharon P.

AU - Yen, Yun

AU - Liu, Xiyong

AU - Ellenhorn, Joshua

AU - Lim, Dean

AU - Paz, Benjamin

AU - Somlo, George

AU - Vora, Nayana

AU - Shibata, Stephen

PY - 2009/5/1

Y1 - 2009/5/1

N2 - The aim of this study was to determine the presence of high-risk HPV-16 in patients with HNSCC, assess the impact of HPV status on treatment response and survival in this select cohort treated with combined modality therapy and to identify the differences in HIF-1α and VEGF expression in HPV-positive and -negative tumors. Patients and Methods: Patients had resectable, untreated stage III, IV HNSCC of the oral cavity, oropharynx, hyopharynx or larynx, and stage II cancer of the base of tongue, hypopharynx and larynx. HPV status was determined by conventional PCR in fresh frozen biopsy samples and by Taqman PCR assay on formalin-fixed, paraffin-embedded specimens. HIF-1α and VEGF expression were assessed by quantitative real-time PCR (RT-PCR). Multivariate Cox proportional hazards regression analysis was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) based on HPV status. Results: HPV-16 was detected in 14 of 24 evaluable cases. There were no significant differences in response rates after neoadjuvant chemotherapy (86% vs. 90%) in HPV-positive and HPV-negative patients, respectively. There was a trend toward better progression-free (HR=0.15, 95% CI=0.002-12.54; p=0.06) and overall survival (HR=0.14, 95% CI=0.001-14.12; p=0.10) for HPV-positive patients. In a subset of 13 fresh frozen samples, RT-PCR revealed a significant increase in VEGF mRNA levels in HPV-positive tumors (p<0.01).No difference was seen for HIF-1α expression. Conclusion: HPV presence portended a better prognosis in patients with oropharyngeal SCC treated with a multimodality treatment in a prospective clinical trial. The level of VEGF mRNA was up-regulated in HPV-16-positive tumors possibly through an HIF-1 independent manner.

AB - The aim of this study was to determine the presence of high-risk HPV-16 in patients with HNSCC, assess the impact of HPV status on treatment response and survival in this select cohort treated with combined modality therapy and to identify the differences in HIF-1α and VEGF expression in HPV-positive and -negative tumors. Patients and Methods: Patients had resectable, untreated stage III, IV HNSCC of the oral cavity, oropharynx, hyopharynx or larynx, and stage II cancer of the base of tongue, hypopharynx and larynx. HPV status was determined by conventional PCR in fresh frozen biopsy samples and by Taqman PCR assay on formalin-fixed, paraffin-embedded specimens. HIF-1α and VEGF expression were assessed by quantitative real-time PCR (RT-PCR). Multivariate Cox proportional hazards regression analysis was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) based on HPV status. Results: HPV-16 was detected in 14 of 24 evaluable cases. There were no significant differences in response rates after neoadjuvant chemotherapy (86% vs. 90%) in HPV-positive and HPV-negative patients, respectively. There was a trend toward better progression-free (HR=0.15, 95% CI=0.002-12.54; p=0.06) and overall survival (HR=0.14, 95% CI=0.001-14.12; p=0.10) for HPV-positive patients. In a subset of 13 fresh frozen samples, RT-PCR revealed a significant increase in VEGF mRNA levels in HPV-positive tumors (p<0.01).No difference was seen for HIF-1α expression. Conclusion: HPV presence portended a better prognosis in patients with oropharyngeal SCC treated with a multimodality treatment in a prospective clinical trial. The level of VEGF mRNA was up-regulated in HPV-16-positive tumors possibly through an HIF-1 independent manner.

KW - Human papillomavirus

KW - Hypoxia-inducible factor-1α

KW - Oropharyngeal squamous cell carcinoma

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=67650079783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650079783&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 1467

EP - 1474

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -